At Biorg, we’re transforming how therapies are developed. The current method of drug discovery is outdated: it takes years and enormous investment and produces results that routinely fail to predict outcomes in humans. Each year, the pharmaceutical industry spends over $171 billion on research to test new drugs, including $52 billion on pre-clinical studies – but over 99% of drug candidates fail. A single failed drug could cost more than $1 billion.
Our mission is to commercialize organ-like constructs that are predictive of human response and bridge a gap between currently available in vitro methods and in vivo models. We look to partner with and empower researchers to create safer novel compounds while reducing time, cost, and the need for animal studies.
Biorg’s technologies are based on the groundbreaking work of its founder, Dr. Anthony Atala, director of the Wake Forest Institute for Regenerative Medicine (WFIRM) in Winston Salem, NC. A world-renowned leader in the field of regenerative medicine, Dr. Atala was recognized by Scientific American in 2015 as one of the world’s most influential people in biotechnology, and by U.S. News & World Report in 2009 as one of 14 Pioneers of Medical Progress in the 21st Century. Dr. Atala and a team of over 400 at WFIRM have successfully grown all or parts of more than 30 organs, including cartilage, bladders, skin, urethras, muscle, vaginas and kidneys. Hundreds of patients have received these fully functioning organs.
Biorg applies WFIRM’s technology to pharmaceutical development, creating self-assembled multi-cellular structures, called spheroids, and miniaturized human organ-like structures, called organoids, to test and develop life-saving drugs. Biorg takes the technologies pioneered at WFIRM, located right in Biorg’s backyard, and develops robust manufacturing processes that generate cost effective, highly reproducible spheroids and organoids – bringing the discoveries from the lab to market, accelerating and refining the drug discovery process, and saving lives.
Spheroids and organoids are only the beginning. Biorg is working towards the next generation of preclinical testing with integrative organoid technologies that reduce species comparison errors and enable testing across a broader range of human cell types. Body-on-a-chip. Personalized medicine. Biorg is bringing these advancements with an eye for the power of these discoveries to prevent and reverse disease progression for millions of people.